AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Entry into a Material Definitive Agreement
ITEM 1.01 Entry into a Material Definitive Agreement.
Effective February 21, 2017, AngioSoma, Inc.s wholly owned
subsidiary, AngioSoma Research, Inc., a Texas corporation,
entered into a Placement Agent and Advisory Services Agreement
(the Agreement) with Boustead Securities, LLC, a California
limited liability company. A copy of the Agreement is attached as
Exhibit 99.1 to this Form 8-K.
Section 3 Securities and Trading Markets
ITEM 3.02 Unregistered Sales of Equity
In connection with the Placement Agent and Advisory Services
Agreement described in Item 1.01, AngioSoma, Inc. will issue
1,000,000 restricted shares of common stock to Boustead
Securities, LLC or its designee(s).
The shares will be issued without registration in reliance on the
exemption in Section 4(a)(2) of the Securities Act of 1933 and
Rule 506(b) of Regulation D thereunder. We believe the exemption
is available because of the substantial preexisting relation with
the parties and the offering was made solely and only to the
parties without any public offering or solicitation.
Section 8 Other Events
ITEM 8.01 Other Events.
AngioSoma, Inc. has moved its principal office to 2500 Wilcrest
Drive, 3rd Floor, Houston, Texas 77042.
Section 9 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits.
Placement Agent and Advisory Services Agreement dated
AngioSoma, Inc. (OTCMKTS:SOAN) Recent Trading Information
AngioSoma, Inc. (OTCMKTS:SOAN) closed its last trading session up +0.0001 at 0.0600 with shares trading hands.